P2RY12 and myocardial infarction: TALOS-AMI trial (30) provided evidence that immediate switching from potent P2Y12 inhibitor to clopidogrel after the acute phase is non-inferior for patients suffering from acute myocardial infarction and significantly reduces bleeding risk compared to continued novel P2Y12 antagonists.